Building a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene Testing
Hiemenz MC, Kadauke S, Lieberman DB, Roth DB, Zhao J, Watt CD, Daber RD, Morrissette JJ. PLoS One. 2016 Apr 4;11(4):e0152851. doi: 10.1371/journal.pone.0152851.
The Center for Personalized Diagnostics (CPD) has compared tumor profiling by next-generation sequencing (NGS) with single-gene tests, and found that the results agreed most of the time, suggesting that NGS is a reliable platform for routine clinical use. In total, the CPD has now sequenced over 5,500 tumor samples.
Article in GenomeWeb [paywalled]